I agree Seel, Kevetrin is absolutely the name of

I agree Seel, Kevetrin is absolutely the name of the game here, everything else is just a bonus/secondary. (which says alot, considering the possibilities that are ever present with Brilacidin, Prurisol, and the rest of the preclinicals, most notably KM391, the autism compound).

With all of the recent discussions about what some may perceive as glaring red flags, some perceive as trivial non-issues, and some are somewhere in between, it all just reiterates the importance of the Kevetrin trial for this company and investors alike.

The Kevetrin DF trial advancement is still single handedly the most important ongoing development in CTIX. For even the most skeptical follower/investor of CTIX, you can't discount or dismiss the fact that Kevetrin is progressing very well at Dana Farber. From what was presented at R&R, we saw clear as day the obvious signs of positive activity at 20-30mg/m2, so what is reasonably possible at 110mg/m2? or 150mg/m2 as cohort 7 will likely be?? For even the biggest skeptics of management, this should serve as a source of stability/confidence in this company moving forward.  

We know that without a doubt the Phase 1 trial of K will be seen through to its end with DF extracting the best possible results. This is something that should be a source of optimism for any investor. In a sense, Kevetrin is out of the hands of management until K phase 1 is completed, and each and every day there is substantive and tangible human clinical trial progress being made. This is progress that I believe will soon prove to be worth a great deal of value to shareholders. 

So as bunny likes to put it, I think great advances in company maturity and stock price are 'just around the corner'. But the difference between CTIX and other companies that are 'just around the corner' are that our most important compound is already moving along through the FDA regulatory pathway, with Brilacidin set to launch very soon into further human trials. In this sense, you have to give credit to management - they are keeping clinical progress moving along as best as they can, IMO. (I know some are unhappy/skeptical with the Prurisol strategy, but I believe the Brilacidin acquisition simply brought a more attractive/easier short term option to the company to pursue partnerships)

Of course, as we continue to move forward, very important elements such as announcing a BOD, uplisting, and seeing institutional investment will be mandatory necessities to help the company further mature. I believe this will come soon, as in my mind Kevetrin is at a point where it's "too good to fail". I say that from a purely minimalistic perspective, in that I believe K is at a point where at a bare minimum it is already justified to advance it to phase 2 trials. Of course, if the results up to now are as good as I dare hope, and if we can safely carry through a few more cohorts, I beleive that a Breakthrough Therapy designation from the FDA is not far away - another absolutely transformational moment for the company.

At that point, I anticipate a violent move up in stock price that will make the past 12 months of range bound stock price a distant memory. I am here for Kevetrin, and I continue to believe it is an absolute game changer. I am very much looking forward to JPM, where I believe we will see a "sequel" to R&R presentation with more up to date cohort update and details.

I wish everyone the best in their investments, and respect all points of view, just sharing my candid opinion. Happy Holidays!